Evidence map›Paper›PMID 34107591›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Significance of lipidomics in liver fibrosis].

S Chen, C Q Yang

Open access · greenAbstract read
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

S ChenDepartment of Gastroenterology and Hepatology,Institution of Digestive Diseases,Tongji Hospital,Tongji University,Shanghai 200065, China.
C Q YangDepartment of Gastroenterology and Hepatology,Institution of Digestive Diseases,Tongji Hospital,Tongji University,Shanghai 200065, China.
Tongji University · CN

Funding

Clinical Research Plan of SHDC SHDC2020CR2030BNational Natural Science Foundation of China 81670571, 81820108006Shanghai Clinical Key Specialty Project SHSLCZDZK06801
6 · The paper itself

Abstract

Chronic liver diseases caused by a variety of causes can lead to the formation of liver fibrosis, and further develop into liver cirrhosis, which is a serious threat to human life and health. As a new research field, lipidomics has been developing vigorously in recent years and has shown great potential in the field of liver fibrosis research. This article introduces lipidomics technology, and discusses its pathogenesis, lipotoxicity biomarkers and emerging therapeutic targets, so as to provide a prospects for the future development of lipidomics in the field of liver fibrosis.

Indexed as

LipidomicsLiver DiseasesBiomarkersHumansLipid MetabolismLiver CirrhosisBiomarkersDiagnosisLipidomicsLiver cirrhosisTreatment

Identifiers

PMID34107591
PMCPMC12813819
OpenAlexW3166049586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.